

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4927954

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
IN CHEOL KANG	04/09/2018
RECEIVING PARTY DATA	
Name:	INNOPHARMASCREEN INC.
Street Address:	404, GRADUATE SCHOOL OF VENTURE, 20 HOSEO-RO 79BEON-GIL
Internal Address:	BAEBANG-EUP, ASAN-SI
City:	CHUNGCHEONGNAM-DO
State/Country:	KOREA, REPUBLIC OF
Postal Code:	31499
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15768374
CORRESPONDENCE DATA	
Fax Number:	(202)223-1879
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-794-6300
Email:	khoward@rubinrudman.com, sliu@rubinrudman.com, USPat@rubinrudman.com
Correspondent Name:	RUBIN AND RUDMAN LLP
Address Line 1:	800 CONNECTICUT AVENUE, N.W.
Address Line 2:	SUITE 400
Address Line 4:	WASHINGTON, D.C. 20006
ATTORNEY DOCKET NUMBER:	19933-0020002
NAME OF SUBMITTER:	XIAOXIANG LIU
SIGNATURE:	/Xiaoxiang Liu Reg No 63566/
DATE SIGNED:	04/23/2018
Total Attachments: 2	
source=19933-0020002_Assignment_signed#page1.tif	
source=19933-0020002_Assignment_signed#page2.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to the undersigned inventor, **In Cheol Kang** hereby sells and assigns to **INNOPHARMASCREEN INC.**, a corporation whose mailing address is 404, Graduate School of Venture, 20, Hoseo-ro 79beon-gil, Baebang-eup, Asan-si Chungcheongnam-do 31499 Republic of Korea, (hereafter referred to as the Assignee), his entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as “COMPOSITION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ATOPIC DERMATITIS,” for which application has an international filing date of October 12, 2016 (also known as International Appl. No. PCT/KR2016/011434), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor’s certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee, its successors, legal representatives and assigns may deem necessary or expedient.

The undersigned inventor agrees to execute all papers necessary in connection with any ex parte or inter partes proceedings or patent enforcement actions (judicial or otherwise) related to the applications or Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee, its successors, legal representatives, and assigns in every reasonable way possible in obtaining evidence and going forward with such ex parte or inter partes proceedings or patent enforcement actions.

The undersigned inventor agrees to perform all affirmative acts at Assignee's, its successors', legal representatives', and assigns' request and expense that may be necessary to obtain or ensure a grant of a valid patent(s).

The undersigned inventor hereby represents that he has full right and authority to convey the entire interest herein assigned, and that Assignors have not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 141404** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventor hereby represents that he understands that the patent practitioners associated with **CUSTOMER NUMBER 141404** are the legal representatives of, and attorneys for, the Assignee, and are NOT the legal representatives of, and attorneys for, the inventor.

IN WITNESS WHEREOF, executed by the undersigned inventor on the date opposite his name.

Date: 04/09/2018

Signature of Inventor: 
In Cheol KANG